INDIANAPOLIS, Sept. 27, 2018 /PRNewswire/ — Eli Lilly and Company (NYSE: LLY) announced today that the U.S. Food and Drug Administration (FDA) has approved Emgality (galcanezumab-gnlm) 120 mg injection for the preventive treatment of migraine in…Original Article
FDA Approves Emgality (galcanezumab-gnlm) for the Preventive Treatment of Migraine in Adults
